3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1
3
Phase NA
1
Phase 2/3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
2
Myelodysplastic Syndromes
1
Interventions
Cyclophosphamide
5
fludarabine phosphate
4
Azacitidine
4
Gemtuzumab
3
Decitabine
3
Cytarabine
3
Busulfan
3
venetoclax
2
Thiotepa
2
Radiotherapy
2
Methylprednisolone
2
Melphalan
2
Filgrastim
2
Etoposide
2
Antilymphocyte Serum
2
vosaroxin
1
vedolizumab
1
tipifarnib
1
midostaurin
1
imetelstat
1
cedazuridine
1
baricitinib
1
Whole-Body Irradiation
1
Tretinoin
1
Tacrolimus
1
Stem Cell Transplantation
1
Nuclear Receptor Subfamily 4, Group A, Member 2
1
Nivolumab
1
Methotrexate
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Myelodysplastic Syndromes
×
CPX-351
×
Clear all
NCT02272478
2020-01-23
AML18
Cardiff University
Phase 2/3
Unknown
1,600 enrolled